用于治疗过敏性鼻炎、慢性鼻-鼻窦炎和鼻息肉的生物制剂。
Biologics for the Treatment of Allergic Rhinitis, Chronic Rhinosinusitis, and Nasal Polyposis.
机构信息
Department of Medicine, Asthma and Allergic Disease Center, University of Virginia Health Systems, Charlottesville, VA 22908-1355, USA.
Department of Medicine, Asthma and Allergic Disease Center, University of Virginia Health Systems, Charlottesville, VA 22908-1355, USA; Department of Microbiology, Asthma and Allergic Disease Center, University of Virginia Health Systems, Charlottesville, VA 22908-1355, USA.
出版信息
Immunol Allergy Clin North Am. 2020 Nov;40(4):539-547. doi: 10.1016/j.iac.2020.06.001. Epub 2020 Sep 9.
Abstract
Allergic rhinitis (AR), most presentations of nasal polyposis (NP), and many presentations of chronic rhinosinusitis are type 2 disorders characterized by expression of interleukin (IL)-4, IL-5, and IL-13. Neutralization of IgE with anti-IgE (omalizumab) has proven efficacy in AR. Similarly, in addition to anti-IgE, blockade of IL-5/IL-5 (mepolizumab, reslizumab, benralizumab) and dual blockade of IL-4 and IL-13 with anti-IL-4R (dupilumab) have demonstrated efficacy in NP. However, these agents are expensive and future studies are essential to evaluate cost effectiveness in comparison with current medical and surgical therapies. This article reviews biologics as potential interventions in AR, chronic rhinosinusitis, and NP.
摘要
变应性鼻炎（AR）、大多数鼻息肉（NP）表现形式和许多慢性鼻-鼻窦炎表现形式均为 2 型疾病，其特征是白细胞介素（IL）-4、IL-5 和 IL-13 的表达。抗 IgE（奥马珠单抗）中和 IgE 已被证明对 AR 有效。同样，除了抗 IgE 外，阻断 IL-5/IL-5（美泊利单抗、瑞利珠单抗、贝那利珠单抗）和双重阻断 IL-4 和 IL-13 的抗 IL-4R（度普利尤单抗）已被证明对 NP 有效。然而，这些药物价格昂贵，未来的研究对于评估其与当前的药物和手术治疗相比的成本效益至关重要。本文综述了生物制剂作为 AR、慢性鼻-鼻窦炎和 NP 的潜在干预措施。
相似文献
1
Biologics for the Treatment of Allergic Rhinitis, Chronic Rhinosinusitis, and Nasal Polyposis.用于治疗过敏性鼻炎、慢性鼻-鼻窦炎和鼻息肉的生物制剂。
Immunol Allergy Clin North Am. 2020 Nov;40(4):539-547. doi: 10.1016/j.iac.2020.06.001. Epub 2020 Sep 9.
2
Biologic Therapies for Allergic Rhinitis and Nasal Polyposis.变应性鼻炎和鼻息肉的生物学治疗。
Curr Allergy Asthma Rep. 2021 Jun 10;21(6):36. doi: 10.1007/s11882-021-01013-y.
3
The Role of Biologics in the Treatment of Nasal Polyps.生物制剂在鼻息肉治疗中的作用。
Immunol Allergy Clin North Am. 2020 May;40(2):295-302. doi: 10.1016/j.iac.2019.12.006. Epub 2020 Jan 8.
4
Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab.伴有鼻息肉的慢性鼻-鼻窦炎：通过靶向抑制 IL-4Rα阻断 IL-4 和 IL-13 治疗的机制见解。
Expert Rev Clin Immunol. 2020 Dec;16(12):1115-1125. doi: 10.1080/1744666X.2021.1847083. Epub 2020 Nov 15.
5
Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.贝那鲁肽对伴有严重哮喘的变应性慢性鼻-鼻窦炎和鼻息肉的实际影响。
Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420950851. doi: 10.1177/2058738420950851.
6
The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma.《降低通胀法案》：对 Medicare 支出以及生物疗法在伴有鼻息肉和哮喘的慢性鼻-鼻窦炎中的可及性的影响。
Int Forum Allergy Rhinol. 2024 Jul;14(7):1261-1265. doi: 10.1002/alr.23344. Epub 2024 Mar 11.
7
Nasal interleukin-5, immunoglobulin E, eosinophilic cationic protein, and soluble intercellular adhesion molecule-1 in chronic sinusitis, allergic rhinitis, and nasal polyposis.慢性鼻窦炎、变应性鼻炎和鼻息肉中鼻腔白细胞介素-5、免疫球蛋白E、嗜酸性阳离子蛋白及可溶性细胞间黏附分子-1
Laryngoscope. 2000 Jun;110(6):1056-62. doi: 10.1097/00005537-200006000-00031.
8
Biologics in Chronic Rhinosinusitis: Current and Emerging.慢性鼻-鼻窦炎中的生物制剂：现状与展望
Immunol Allergy Clin North Am. 2024 Nov;44(4):657-671. doi: 10.1016/j.iac.2024.07.005. Epub 2024 Aug 17.
9
Biologics for chronic rhinosinusitis with nasal polyps.生物制剂治疗慢性鼻-鼻窦炎伴鼻息肉
J Allergy Clin Immunol. 2020 Mar;145(3):725-739. doi: 10.1016/j.jaci.2020.01.020.
10
Monoclonal Antibodies for the Treatment of Nasal Polyps.用于治疗鼻息肉的单克隆抗体
Immunol Allergy Clin North Am. 2017 May;37(2):357-367. doi: 10.1016/j.iac.2017.01.008. Epub 2017 Mar 2.
引用本文的文献
1
Interleukin 8 Molecular Interplay in Allergic Rhinitis and Chronic Rhinosinusitis with Nasal Polyps: A Scoping Review.变应性鼻炎和伴鼻息肉的慢性鼻-鼻窦炎中白细胞介素8的分子相互作用：一项范围综述
Life (Basel). 2025 Mar 15;15(3):469. doi: 10.3390/life15030469.
2
Correlation between monocyte and length of in-hospital stay in patients with allergic rhinitis: data from the MIMIC-IV database.过敏性鼻炎患者单核细胞与住院时长的相关性：来自MIMIC-IV数据库的数据
BMC Anesthesiol. 2025 Mar 4;25(1):113. doi: 10.1186/s12871-025-02979-2.
3
Insufficiency of Laboratory Data in Reflecting Allergic Rhinitis Severity Based on the Allergic Rhinitis and Its Impact on Asthma Guideline in Korean Patients.基于韩国患者变应性鼻炎及其对哮喘影响的指南，实验室数据在反映变应性鼻炎严重程度方面的不足
J Rhinol. 2024 Mar;31(1):17-21. doi: 10.18787/jr.2023.00066. Epub 2024 Mar 31.
4
The sinus surgery completeness score: a radiological assessment of the extent of endoscopic sinus surgery.鼻窦手术完整性评分：内镜鼻窦手术范围的影像学评估
Eur Arch Otorhinolaryngol. 2025 Mar;282(3):1301-1309. doi: 10.1007/s00405-024-09110-0. Epub 2024 Dec 4.
5
V Brazilian Consensus on Rhinitis - 2024.第五届巴西鼻炎共识 - 2024年
Braz J Otorhinolaryngol. 2025 Jan-Feb;91(1):101500. doi: 10.1016/j.bjorl.2024.101500. Epub 2024 Sep 7.
6
Blood and local eosinophil levels in chronic rhinitis: Observations during seasonal allergen exposure and non-exposure.慢性鼻炎患者血液及局部嗜酸性粒细胞水平：季节性变应原暴露期与非暴露期的观察结果
World Allergy Organ J. 2024 Jul 4;17(7):100930. doi: 10.1016/j.waojou.2024.100930. eCollection 2024 Jul.
7
Efficacy, Safety, and Continuation of Biological Therapy in Older Patients with Asthma in a Real-World Setting: A Retrospective Observational Study.真实世界中老年哮喘患者生物治疗的疗效、安全性及持续性：一项回顾性观察研究
Yonago Acta Med. 2024 Apr 22;67(2):114-123. doi: 10.33160/yam.2024.05.003. eCollection 2024 May.
8
Efficacy and Safety of Monoclonal Antibodies for the Treatment of Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.单克隆抗体治疗嗜酸性食管炎的疗效与安全性：随机对照试验的系统评价与荟萃分析
Dig Dis Sci. 2024 Jul;69(7):2530-2539. doi: 10.1007/s10620-024-08413-w. Epub 2024 May 6.
9
A Review on Novel Therapeutic Modalities and Evidence-based Drug Treatments against Allergic Rhinitis.过敏性鼻炎的新型治疗方式及循证药物治疗综述
Curr Pharm Des. 2024;30(12):887-901. doi: 10.2174/0113816128295952240306072100.
10
Recent advances in mass spectrometry-based proteomics and metabolomics in chronic rhinosinusitis with nasal polyps.基于质谱的蛋白质组学和代谢组学在慢性鼻-鼻窦炎伴鼻息肉中的最新进展。
Front Immunol. 2023 Sep 6;14:1267194. doi: 10.3389/fimmu.2023.1267194. eCollection 2023.
本文引用的文献
1
Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials.奥马珠单抗治疗过敏性鼻炎的临床疗效与安全性：随机临床试验的系统评价与荟萃分析
Am J Rhinol Allergy. 2020 Mar;34(2):196-208. doi: 10.1177/1945892419884774. Epub 2019 Nov 1.
2
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.度普利尤单抗治疗伴有鼻息肉的重度慢性鼻-鼻窦炎患者的疗效和安全性（LIBERTY NP SINUS-24 和 LIBERTY NP SINUS-52）：两项多中心、随机、双盲、安慰剂对照、平行分组 3 期临床试验的结果。
Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19.
3
Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis.慢性鼻-鼻窦炎的炎症表型与临床表现的相关性。
J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2812-2820.e3. doi: 10.1016/j.jaip.2019.05.009. Epub 2019 May 22.
4
Allergic conversion of protective mucosal immunity against nasal bacteria in patients with chronic rhinosinusitis with nasal polyposis.变应性转换对慢性鼻-鼻窦炎伴鼻息肉患者鼻黏膜局部细菌防御免疫的影响
J Allergy Clin Immunol. 2019 Mar;143(3):1163-1175.e15. doi: 10.1016/j.jaci.2018.07.006. Epub 2018 Jul 25.
5
Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma.度普利尤单抗治疗常年变应性鼻炎及合并哮喘的疗效和安全性。
J Allergy Clin Immunol. 2018 Jul;142(1):171-177.e1. doi: 10.1016/j.jaci.2017.11.051. Epub 2018 Jan 31.
6
Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study.奥马珠单抗治疗伴有鼻息肉和哮喘的慢性鼻-鼻窦炎：一项真实世界研究。
Rhinology. 2018 Mar 1;56(1):42-45. doi: 10.4193/Rhino17.139.
7
Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial.美泊利珠单抗可减少重度鼻息肉患者的手术需求：一项随机试验。
J Allergy Clin Immunol. 2017 Oct;140(4):1024-1031.e14. doi: 10.1016/j.jaci.2017.05.044. Epub 2017 Jul 4.
8
Distribution, subtype population, and IgE positivity of mast cells in chronic rhinosinusitis with nasal polyps.鼻息肉型慢性鼻-鼻窦炎中肥大细胞的分布、亚型及IgE阳性情况
Ann Allergy Asthma Immunol. 2017 Aug;119(2):120-128. doi: 10.1016/j.anai.2017.05.019. Epub 2017 Jun 19.
9
Lack of Efficacy of Symptoms and Medical History in Distinguishing the Degree of Eosinophilia in Nasal Polyps.症状和病史在鉴别鼻息肉嗜酸性粒细胞增多程度方面缺乏疗效。
J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1582-1588.e3. doi: 10.1016/j.jaip.2017.04.009. Epub 2017 May 10.
10
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.美泊利珠单抗附加疗法对严重嗜酸性粒细胞性哮喘（MUSCA）患者健康相关生活质量和哮喘控制标志物的疗效：一项随机、双盲、安慰剂对照、平行分组、多中心、3b 期临床试验。
Lancet Respir Med. 2017 May;5(5):390-400. doi: 10.1016/S2213-2600(17)30125-X. Epub 2017 Apr 5.
Zotero 插件